What is required of an HIV vaccine?

Lancet

Volumn 350, Issue 9091, 1997, Pages 1617-1621

  Bangham, Charles R M ^a   Phillips, Rodney E ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MONKEY; PRIORITY JOURNAL; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0031590576     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03258-3     Document Type: Review

References (45)

1. Holland JJ, de la Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microb Immunol 1992; 176: 1-20.
2. McCune JM. Viral latency in HIV disease. Cell 1995; 82: 183-88.
3. Zhang J, Temin TM. Retrovirus recombination depends on the length of sequence identity and is not error prone. J Virol 1994; 68: 2409-14.
4. Coffin JM. Retroviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 3rd edn. Philadelphia: Lippincott-Raven, 1996: 1767-847.
5. Kestler HW, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65: 651-62.
6. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-41.
7. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasispecies of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.
8. Wolinsky SM, Korber BTM, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272: 537-42.
9. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viraemia in primary human immunodeficiency virus type I syndrome. J Virol 1994; 68: 4650-55.
10. Rinaldo C, Xiao-Li Huang, Zheng Fan, et al. High levels of antihuman immunodeficiency virus type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long term nonprogressors. J Virol 1995; 69: 5838-42.
11. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354: 453-59.
12. Price DA, Goulder PJR, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94: 1890-95.
13. Goulder PJR, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T lymphocyte response associated with progression to AIDS. Nat Med 1997; 3: 212-17.
14. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1 specific CTL during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205-11.
15. Nowak MA, May RM, Phillips RE, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995; 375: 606-11.
16. Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell Activity Antagonized by Naturally Occuring HIV-1 Gag Variants. Nature 1994 369: 403-07.
17. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268: 1612-15.
18. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64.
19. Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2: 767-75.
20. Matteucci D, Pistello M, Mazzetti P, et al. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol 1996; 70: 617-22.
21. Klenerman P, Meier UC, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 1995; 25: 1927-31.
22. McMichael AJ. Immunology. In: Weatherall DJ, Ledingham JG, Warrell DA, eds. Oxford Textbook of Medicine, 3rd edn. Oxford: Oxford University Press, 1995: 141-54.
23. Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature 1986; 322: 747-48.
24. Pincus SH, Cole R, Ireland R, McAtee F, Fujisawa R, Portis J. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol 1995; 69: 7152-58.
25. Amor S, Scallan MF, Morris MM, Dyson H, Fazakerley JK. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. J Gen Virol 1996; 77: 281-91.
26. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272: 104-07.
27. Bolin SR, Ridpath JF. Assessment of protection from systemic infection or disease afforded by low to intermediate titers of passively acquired neutralizing antibody against bovine viral diarrhea virus in calves. Am J Vet Res 1995; 56: 755-59.
28. Schutten M, Tenner-Racz K, Racz P, van Bekkum DW, Osterhaus AD. Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model. J Gen Virol 1996; 77: 1667-75.
29. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv Immunol 1979; 27: 51-177.
30. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-68.
31. Paul WE. Can the immune response control HIV infection? Cell 1995; 82: 177-82.
32. Wigzell H. Prospects for an HIV vaccine. Fed Am Soc Exp Biol J 1991; 5: 2406-11.
33. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-49.
34. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995; 95: 341-49.
35. Aebischer T, Moskophidis D, Rohrer UH, Zinkernagel RM, Hengartner H. In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc Nat Acad Sci USA 1991; 88: 11047-51.
36. Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1: 330-36.
37. Weidt G, Deppert W, Utermohlen O, Heukeshoven J, Lehmann-Grube F. Emergence of virus escape mutants after immunization with epitope vaccine. J Virol 1995; 69: 7147-51.
38. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-76.
39. Molla A, Korneyeva M, Qing Gao, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760-66.
40. Putkonen P, Walther L, Zhang Y-J, et al. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nat Med 1995; 1: 914-18.
41. Ruprecht RM, Mullaney S, Bernard LD, et al. Vaccination with a live retrovirus: the nature of the protective immune response. Proc Nat Acad Sci USA 1990; 87: 5558-62.
42. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995; 345: 1342-44.
43. Bachmann MF, Kalinke U, Althage A, et al. The role of antibody concentration and avidity in antiviral protection. Science 1997; 276: 2024-27.
44. Cohen J. The daunting challenge of keeping HIV suppressed. Science 1997; 277: 32-33.
45. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188-91.